Viral safety of coagulation factor concentrates: memoirs from an insider
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 16 (4) , 630-633
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Prevalence of Infection with the Hepatitis C Virus among Italian Hemophiliacs before and after the Introduction of Virally Inactivated Clotting Factor Concentrates: A Retrospective EvaluationVox Sanguinis, 1994
- Absence of Hepatitis after Treatment with a Pasteurized Factor VIII Concentrate in Patients with Hemophilia and No Previous TransfusionsNew England Journal of Medicine, 1987
- LIVER DISEASE IN HAEMOPHILIAThe Lancet, 1986
- WET HEATING FOR SAFER FACTOR VIII CONCENTRATE?The Lancet, 1985
- High risk of non‐A non‐B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulinBritish Journal of Haematology, 1985
- HAEMOPHILIA AND AIDSThe Lancet, 1985
- Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)Science, 1983
- T-Lymphocyte Subpopulations in Patients with Classic Hemophilia Treated with Cryoprecipitate and Lyophilized ConcentratesNew England Journal of Medicine, 1983
- Impaired Cell-Mediated Immunity in Patients with Classic HemophiliaNew England Journal of Medicine, 1983
- Asymptomatic liver disease in haemophiliacs.Journal of Clinical Pathology, 1975